Cytograft's New Lifeline for Vascular Surgery
This article was originally published in Start Up
Executive Summary
The creation of durable vascular grafts has been a tantalizing objective for multitudes of companies and research efforts that have applied all the disciplines of medical science to it: tissue engineering, cell-therapies, biomaterials, drugs, and combinations of all of those technologies, but without much success. The complexities of creating a functional structure with biological properties has foiled many a research effort. But now Cytograft Tissue Engineering has a new take on tissue engineering. Cytograft produces a living conduit with the handling properties of a native vessel, built exclusively from the patient's own cells. Unlike previous approaches, Cytograft's Lifeline vascular graft does not require synthetic materials or exogenous scaffolds.
You may also be interested in...
European Markets for Prosthetic Vascular Grafts
Many large and growing diseases, such as diabetes, cause vessel damage calling for replacement vascular grafts. The European market for prosthetic vascular grafts is today a $343 million industry and growing, according to "The European Prosthetic Vascular Grafts Market," a report just issued y Medtech Insight.
Convergence and Complexity in Cardiac Regeneration
In heart failure, companies with expertise in gene or cell biology, or percutaneous delivery devices, see the first application where regenerative medicine could finally realize its promise. The enormous patient population, the high mortality of the disease, and the economics of treating it today provide a multi-billion dollar opportunity for which it's worth braving the complexity of cell therapy for tissue repair. Indeed, first-generation autologous heart cell therapies involve many different types of expertise resident in companies with different mindsets. Unknowns dog every component of the therapies on the level of basic biology. Still to be worked out: the right cell types; the optimal delivery route and device; when and at what dose cells should be administered, and in combination with which genes or drugs. Nevertheless, the great need in heart failure keeps companies dedicated to cardiac regeneration therapies. And as the cell therapy developers reveal new discoveries about the innate regenerative powers of the heart, drug developers are starting to move in, promising a much simpler approach than the combination products presently in the works.
Wound Solutions Ltd.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.